Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma
暂无分享,去创建一个
Hong Zhang | J. Bradner | S. Trabucco | R. Gerstein | Hong Zhang | A. Evens | D. Greiner | L. Shultz | Dale L Greiner | Leonard D Shultz | James E Bradner | Sally E Trabucco | Rachel M Gerstein | Andrew M Evens
[1] Charles Y. Lin,et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. , 2013, Cancer cell.
[2] F. Speleman,et al. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma , 2013, Oncotarget.
[3] Travis J Cohoon,et al. Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.
[4] J. Garin,et al. Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers , 2013, EMBO molecular medicine.
[5] S. Knapp,et al. BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia , 2013, Blood Cancer Journal.
[6] David A. Orlando,et al. Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.
[7] X. Zhao,et al. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity , 2013, Leukemia.
[8] A. Rosenwald,et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. , 2013, Blood.
[9] Reid C Thompson,et al. Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma , 2013, Clinical Cancer Research.
[10] David Dunson,et al. Genetic heterogeneity of diffuse large B-cell lymphoma , 2013, Proceedings of the National Academy of Sciences.
[11] J. Bradner,et al. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML) , 2012, Oncotarget.
[12] Christopher J. Ott,et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. , 2012, Blood.
[13] L. Staudt,et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Paul Shinn,et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. , 2012, Cancer cell.
[15] Eric S. Lander,et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing , 2012, Proceedings of the National Academy of Sciences.
[16] J. Friedberg. Relapsed/refractory diffuse large B-cell lymphoma. , 2011, Hematology. American Society of Hematology. Education Program.
[17] S. Lowe,et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.
[18] P. Sandy,et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.
[19] R. Young,et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.
[20] Steven J. M. Jones,et al. Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.
[21] Raul Rabadan,et al. Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.
[22] Elias Campo,et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. , 2011, Blood.
[23] Joseph M. Connors,et al. Oncogenically active MYD88 mutations in human lymphoma , 2011, Nature.
[24] Raul Rabadan,et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma , 2010, Nature.
[25] Govind Bhagat,et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. , 2010, Cancer cell.
[26] William B. Smith,et al. Selective inhibition of BET bromodomains , 2010, Nature.
[27] B. Coiffier,et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.
[28] Jan Delabie,et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma , 2010, Nature.
[29] Ryan D. Morin,et al. Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin , 2010, Nature Genetics.
[30] R. Gascoyne,et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.
[31] G. Saglio,et al. Molecular pathogenesis of diffuse large B-cell lymphoma , 2009 .
[32] S. Ogawa,et al. Frequent inactivation of A20 in B-cell lymphomas , 2009, Nature.
[33] R. Dalla‐Favera,et al. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma , 2009, Nature.
[34] H. Drexler,et al. t(3;7)(q27;q32) fuses BCL6 to a non-coding region at FRA7H near miR-29 , 2008, Leukemia.
[35] Jan Delabie,et al. Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma , 2008, Science.
[36] R. Aguiar,et al. Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma. , 2008, Cancer genetics and cytogenetics.
[37] L. Staudt,et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma , 2007, Leukemia.
[38] P. Koduru,et al. Diffuse large B-cell lymphoma with a novel translocation involving BCL6. , 2007, Cancer genetics and cytogenetics.
[39] W. Chan,et al. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. , 2006, Blood.
[40] Stefano Monti,et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma , 2006, The Journal of experimental medicine.
[41] Kajia Cao,et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. , 2004, The American journal of pathology.
[42] T. Golub,et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. , 2003, Blood.
[43] Adrian Wiestner,et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[44] L. Staudt,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[45] M. Minden,et al. Molecular cytogenetic characterization of non‐Hodgkin lymphoma cell lines , 2002, Genes, chromosomes & cancer.
[46] Todd,et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.
[47] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[48] N. Berinstein,et al. Alterations of the p53 tumor suppressor gene in diffuse large cell lymphomas with translocations of the c-MYC and BCL-2 proto-oncogenes. , 1994, Blood.
[49] G. Gaidano,et al. In vitro establishment of AIDS-related lymphoma cell lines: phenotypic characterization, oncogene and tumor suppressor gene lesions, and heterogeneity in Epstein-Barr virus infection. , 1993, Leukemia.
[50] R. Levy,et al. Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines , 1978, Cancer.
[51] A. Epstein,et al. Biology of the human malignant lymphomas. , 1978, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[52] A. Chadli. THE CANCER CELL , 1924, La Presse medicale.